Folic acid (Vitamin B9) 是一种来自维生素 B 群的口服活性必需营养素。Folic acid 具有抗抑郁样作用。Folic acid 可降低新生儿神经管缺陷的风险。Folic acid 可用于治疗因叶酸缺乏引起的巨幼红细胞性贫血和大红细胞性贫血。
生物活性 | Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the treatment of megaloblastic and macrocytic anemias due to folic deficiency[1][2][3][4]. |
IC50& Target | Human Endogenous Metabolite | Microbial Metabolite |
|
体外研究 (In Vitro) | Folic acid plays a critical role in the prevention of chromosome breakage and hypomethylation of DNA[1].
|
体内研究 (In Vivo) | Folic acid (10, 50, 100 mg/kg; p.o.) shows an antidepressant-like effect in this
behavioral mouse model[2]. Folic acid (1, 10 nmol/site) shows no psychostimulant effect in mice habituated to the novel environment[2]. Folic acid (1, 5 mg/kg; p.o.) prevents epigenetic modification of hepatic gene expression in the offspring in rats[3].
Animal Model: | 30-40 g swiss mice[2] | Dosage: | 10, 50, 100 mg/kg | Administration: | Oral administration | Result: | Decreased the immobility time in the forced swimming test (FST) (F324=11.21) and produced a significant effect in the immobility time in the tail suspension test (TST) (F3,20=5.71). |
Animal Model: | 30-40 g swiss mice[2] | Dosage: | 1-10 nmol/site | Administration: | Intracerebroventrical injection | Result: | Decreased the immobility time of mice in the FST (F3,22=12.31) and TST (F3,22=5.50). |
Animal Model: | Virgin female Wistar rats[3] | Dosage: | 1, 5 mg/kg (180 g/kg protein with 1 mg/kg folic acid or 90 g/kg casein with 1, 5 mg/kg folic acid) | Administration: | Oral administration | Result: | Prevented epigenetic modification of hepatic gene expression in the offspring. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Ketones, Aldehydes, Acids
|
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: 1M NaOH : 100 mg/mL(226.55 mM;Need ultrasonic) DMSO : 33.33 mg/mL(75.51 mM;Need ultrasonic) H2O :< 0.1 mg/mL(insoluble) 配制储备液 1 mM | 2.2655 mL | 11.3276 mL | 22.6552 mL | 5 mM | 0.4531 mL | 2.2655 mL | 4.5310 mL | 10 mM | 0.2266 mL | 1.1328 mL | 2.2655 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.71 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.08 mg/mL (4.71 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (4.71 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|